4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by 4D Molecular Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 9 filings
- 2 insiders, $3.20M in total
- Insiders trading
- 2
- Net value
- −$3.20M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for 4D Molecular Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Bizily Scott | Chief Legal Officer | 8,617 | Sep 22, 2026 | 11 |
| Kirn David | See Remarks | 767,486 | Sep 16, 2026 | 8 |
| Milligan John F | Director | – | Jun 18, 2026 | 1 |
| Sblendorio Glenn | Director | – | Jun 18, 2026 | 2 |
| Chacko Jacob | Director | 0 | Jun 18, 2026 | 1 |
| Tomasello Shawn | Director | – | Jun 18, 2026 | 1 |
| Theuer Charles | Director | 41,684 | Jun 18, 2026 | 2 |
| Miller-Rich Nancy | Director | – | Jun 18, 2026 | 1 |
| Gray Susannah | Director | – | Jun 18, 2026 | 1 |
| Simms Christopher Paul | See Remarks | – | Mar 27, 2026 | 1 |
| Gupta Ashoo | VP, Finance and Controller | 47,055 | Mar 24, 2026 | 2 |
| Humer Kristian | Chief Financial Officer | – | Dec 11, 2025 | 1 |
| Kamal Fariborz | President & COO | – | Mar 10, 2025 | 0 |
| Mehra Uneek | See Remarks | – | Mar 10, 2025 | 0 |
| Kim Robert Young | Chief Medical Officer | 1,043 | Mar 10, 2025 | 0 |
| RA Capital Healthcare Fund LP | 10% Owner | 4,563,211Indirect | Dec 10, 2024 | 0 |
| Ra Capital Management, L.P. | 10% Owner | 4,563,211Indirect | Dec 10, 2024 | 0 |
| Kolchinsky Peter | 10% Owner | 4,563,211Indirect | Dec 10, 2024 | 0 |
| Shah Rajeev M. | 10% Owner | 4,563,211Indirect | Dec 10, 2024 | 0 |
| Biotechnology Value Fund L P | Other: See Explanation of Responses | 87,911 | Nov 13, 2024 | 0 |
| BVF Partners L P | Other: See Explanation of Responses | 87,911 | Nov 13, 2024 | 0 |
| BVF Inc | Other: See Explanation of Responses | 87,911 | Nov 13, 2024 | 0 |
| Biotechnology Value Fund II LP | Other: See Explanation of Responses | 87,911 | Nov 13, 2024 | 0 |
| Lampert Mark N | Other: See Explanation of Responses | 87,911 | Nov 13, 2024 | 0 |
| Biotechnology Value Trading Fund OS LP | Other: See Explanation of Responses | 87,911 | Nov 13, 2024 | 0 |
| BVF Partners OS Ltd. | Other: See Explanation of Responses | 87,911 | Nov 13, 2024 | 0 |
| BVF I GP LLC | Other: See Explanation of Responses | 87,911 | Nov 13, 2024 | 0 |
| BVF II GP LLC | Other: See Explanation of Responses | 87,911 | Nov 13, 2024 | 0 |
| BVF GP Holdings LLC | Other: See Explanation of Responses | 87,911 | Nov 13, 2024 | 0 |
| Viking Global Investors LP | 10% Owner | 4,247,914Indirect | Jan 5, 2024 | 0 |
| Halvorsen Ole Andreas | 10% Owner | 4,247,914Indirect | Jan 5, 2024 | 0 |
| Ott David C. | 10% Owner | 4,247,914Indirect | Jan 5, 2024 | 0 |
| Viking Global Opportunities Portfolio GP LLC | 10% Owner | 4,247,914Indirect | Jan 5, 2024 | 0 |
| Viking Global Opportunities GP LLC | 10% Owner | 4,247,914Indirect | Jan 5, 2024 | 0 |
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 10% Owner | 4,247,914Indirect | Jan 5, 2024 | 0 |
| Shabet Rose Sharon | 10% Owner | 4,247,914Indirect | Jan 5, 2024 | 0 |
| Viking Global Opportunities Parent GP LLC | 10% Owner | 4,247,914Indirect | Jan 5, 2024 | 0 |
| Kasahara Noriyuki | Director | – | May 25, 2023 | 0 |
| Moretti August J | Chief Financial Officer | 11,045 | May 16, 2023 | 0 |
| Fishman Robert S | Chief Medical Officer | – | Sep 6, 2022 | 0 |
| Zimmermann Carolyne | Chief Business Officer | – | Feb 3, 2022 | 0 |
| Schaffer David | Director | 901,215 | Oct 22, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2026 (view filing)4:06 PM ET | Aug 19 | 2 days | Kirn DavidSee Remarks | SSale | −69.1K | $15.75 | −$1.09M | −7.7%825.8K after | 2 lots10b5-1 |
| Sep 3, 2026 (view filing)6:55 PM ET | Sep 1 | 2 days | Bizily ScottChief Legal Officer | SSale | −584 | $14.00 | −$8.18K | −6.3%8.62K after | 10b5-1 |
| Sep 16, 2026 (view filing)5:13 PM ET | Sep 14 | 2 days | Kirn DavidSee Remarks | SSale | −58.3K | $13.90 | −$811.0K | −7.1%767.5K after | 10b5-1 |
| Sep 22, 2026 (view filing)6:43 PM ET | Sep 16 | 6 daysLate | Bizily ScottChief Legal Officer | SSale | −1.64K | $13.65 | −$22.3K | −15.9%8.62K after | 10b5-1 |